ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Aclarion Inc

Aclarion Inc (ACON)

0.0423
-0.0027
(-6.00%)
마감 18 1월 6:00AM
0.0424
0.0001
(0.24%)
시간외 거래: 9:59AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
0.0424
매수가
0.042
매도가
0.0425
거래량
96,456,984
0.041 일간 변동폭 0.0484
0.033 52주 범위 3.85
market_cap
전일 종가
0.045
개장가
0.0467
최근 거래 시간
1500
@
0.0424
(formt)
마지막 거래 시간
재정 규모
US$ 4,153,939
VWAP
0.043065
평균 볼륨(3m)
15,032,045
발행 주식
10,431,159
배당수익률
-
주가수익률
-0.08
주당순이익(EPS)
-0.47
매출
75k
순이익
-4.91M

Aclarion Inc 정보

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments.

섹터
Medical Laboratories
산업
Medical Laboratories
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Aclarion Inc is listed in the Medical Laboratories sector of the 나스닥 with ticker ACON. The last closing price for Aclarion was US$0.05. Over the last year, Aclarion shares have traded in a share price range of US$ 0.033 to US$ 3.85.

Aclarion currently has 10,431,159 shares in issue. The market capitalisation of Aclarion is US$469,402.16 . Aclarion has a price to earnings ratio (PE ratio) of -0.08.

ACON 최신 뉴스

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer Magazine Published by...

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare...

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare...

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing...

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled...

Aclarion Added to PRISM Emerging Medical Devices Index

Company's industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Michigan's Sheridan Community HospitalPRISM Emerging Medical Devices Index...

Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market

Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population...

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

CLUE is a Multi-center Trial to Identify how Often Nociscan’s AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.0921-68.47583643120.13450.13730.033899287510.04608162CS
4-0.0633-59.88647114470.10570.38690.033479648560.14860979CS
12-0.1726-80.27906976740.2150.38690.033150320450.14881845CS
26-0.2576-85.86666666670.30.38690.03369397890.15207163CS
52-3.1276-98.66246056783.173.850.03344472590.28501603CS
156-46.3576-99.908620689746.464.80.03321913814.5974557CS
260-46.3576-99.908620689746.464.80.03321913814.5974557CS

ACON - Frequently Asked Questions (FAQ)

What is the current Aclarion share price?
The current share price of Aclarion is US$ 0.0424
How many Aclarion shares are in issue?
Aclarion has 10,431,159 shares in issue
What is the market cap of Aclarion?
The market capitalisation of Aclarion is USD 469.4k
What is the 1 year trading range for Aclarion share price?
Aclarion has traded in the range of US$ 0.033 to US$ 3.85 during the past year
What is the PE ratio of Aclarion?
The price to earnings ratio of Aclarion is -0.08
What is the cash to sales ratio of Aclarion?
The cash to sales ratio of Aclarion is 5.56
What is the reporting currency for Aclarion?
Aclarion reports financial results in USD
What is the latest annual turnover for Aclarion?
The latest annual turnover of Aclarion is USD 75k
What is the latest annual profit for Aclarion?
The latest annual profit of Aclarion is USD -4.91M
What is the registered address of Aclarion?
The registered address for Aclarion is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Aclarion website address?
The website address for Aclarion is www.aclarion.com
Which industry sector does Aclarion operate in?
Aclarion operates in the MEDICAL LABORATORIES sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

ACON Discussion

게시물 보기
Surfacetite Surfacetite 7 시간 전
https://www.otcmarkets.com/stock/ACON/news/story?e&id=3107388
👍 1
benhor benhor 13 시간 전
$ACON added some more on today’s dip
👍️0
power11 power11 1 일 전
BANKRUPCY NEXT !! DUMPO GARBAGGIO !!!
👍️0
benhor benhor 2 일 전
$ACON looking good
👍 1
glenn1919 glenn1919 2 주 전
acon................https://stockcharts.com/h-sc/ui?s=acon&p=W&b=5&g=0&id=p86431144783
👍️0
knrorrel knrorrel 2 주 전
ACON 🔥🔥🔥🔥 KABOOOOOOM
👍️0
Surfacetite Surfacetite 2 주 전
https://www.otcmarkets.com/filing/html?id=18085780&guid=Q90-kqGyIgvnJth
👍️0
Surfacetite Surfacetite 2 주 전
Back to .38 please
👍️0
adamski adamski 2 주 전
ACON nice move 😊
👍️0
luckydude777 luckydude777 1 월 전
Sadly - says it about all: "The Company intends to implement a reverse stock split in the near future in order to assist with the Company’s compliance with Nasdaq’s Bid Price Requirement."

I think this company has a technology that can be very useful to humanity, but the heart/cardiology CARTEL does NOT want this technology made available to the public IMO.
👍️0
Werbe Werbe 3 월 전
They must be planning a major share price boost or reverse split, this should be trading on the OTC now if I am not mistaken?
👍️0
shurtha2000 shurtha2000 4 월 전
Personal Injury News was Huge and went unnoticed
👍️0
mining101 mining101 5 월 전
Ready - anytime
👍️0
ollik78 ollik78 5 월 전
Let’s see later
Some PR AH and boom 💥
👍️0
peterus peterus 5 월 전
someone is loading big time at 0.2250s
👍️0
peterus peterus 5 월 전
company did get european patent approval yesterday but no pr out
👍️0
peterus peterus 5 월 전
bought some should see European patent news
👍️0
mining101 mining101 5 월 전
No volume low - wait for it
👍️0
Monksdream Monksdream 5 월 전
ACON new 52 week low
👍️0
mining101 mining101 6 월 전
Looks ready
👍️0
mining101 mining101 6 월 전
When mooning?
👍️0
stock1ace1 stock1ace1 8 월 전
50ma/20ma cross
👍️0
mining101 mining101 8 월 전
Big volume guided the way a few weeks ago
👍️0
Termite7 Termite7 8 월 전
How high of a moon? ....Thanks!!!
👍️0
mining101 mining101 8 월 전
Moon soon
👍️0
Awl416 Awl416 9 월 전
Knock knock… who’s there?
👍️0
luckydude777 luckydude777 10 월 전
Picked up a popcorn bag full earlier at $.328 just for the heck of it.
👍️0
gail gail 10 월 전
grabbed some post market. runs like hell in the past. we shall see.
👍️0
DK11 DK11 10 월 전
Hang on Invest, I am sure you're Bull is coming Lol
👍️0
Invest-in-America Invest-in-America 10 월 전
ACON: "But don't tell my heart, my ACON breaky heart
I just don't think he'd understand;
And if you tell my heart, my ACON breaky heart
He might blow up and kill this man!!"


(Mr. Billy, & his CHARMING Daughter!!!)
👍️0
luckydude777 luckydude777 10 월 전
Company used some of it's pocket change to run the price up over $.09 earlier so they could dump a gazillion under $.08. Hummmmm ....

Seems like a PR (no matter how hokey it might be) would have been a better strategy.

Something to the effect: "We have discovered what we believe to be a revolutionary way to keep our patients from pooping while being given certain treatments. We'll be looking to file a patent on this amazing discovery just as soon as we can raise enough cash to pay for the initial patent fee."
👍️0
luckydude777 luckydude777 10 월 전
NOW we're starting to talk! YEAH BABY!
👍️0
luckydude777 luckydude777 10 월 전
Love these dumping prices. MORE!!!
👍️0
luckydude777 luckydude777 10 월 전
Got some at $.4099 a bit ago. Good price IMO.
👍️0
INFINITI INFINITI 11 월 전
It’s super thin slap that ask
👍️0
INFINITI INFINITI 11 월 전
Yes I saw that
👍️0
ncstrongman ncstrongman 11 월 전
Just announced, CLOSED
👍️0
INFINITI INFINITI 11 월 전
Aclarion Announces Closing of $3.0 Million Public Offering

Source: GlobeNewswire Inc.

via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.58. The common warrants are immediately exercisable at a price of $0.58 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.
Gross proceeds, before deducting placement agent fees and other offering expenses, are approximately $3.0 million.

Maxim Group LLC acted as sole placement agent in connection with this offering.

The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-275989) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the "SEC") on February 26, 2024. The offering was made only by means of a prospectus which is a part of the Registration Statement. A copy of the final prospectus relating to the offering has been filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements.

All of our forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Registration Statement, as well as other disclosures contained in such Registration Statement and the Company’s other filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com

👍️0
INFINITI INFINITI 11 월 전
Closing tomorrow it should go back up
👍️ 1
Sly1969 Sly1969 11 월 전
Sold at 71 cents premarket today after buying at 60 cents and loaded back up under 32 cents on bigger dip. Hope to sell at 50 cents or above
👍️0
Sly1969 Sly1969 11 월 전
Sold at 71 cents premarket today after buying at 60 cents and loaded back up under 32 cents on bigger dip. Hope to sell at 50 cents or above
👍️0
Monksdream Monksdream 11 월 전
ACON new 52 week low
👍️0
Sly1969 Sly1969 11 월 전
Rentry today on dip premarket.. 0.6093 average
👍️0
cottonmather cottonmather 11 월 전
ACON has no technical synchronicity except on the short end. $1 is often a pit stop but that point is showing no favor either. It's on my watchlist but nothing more. https://schrts.co/CYDkRKKW
👍️0
Monksdream Monksdream 11 월 전
ACON new 52 week low
👍️0
Monksdream Monksdream 11 월 전
ACON new 52 week low
👍️0
Monksdream Monksdream 11 월 전
ACON new 52 week low
👍️0
Monksdream Monksdream 11 월 전
ACON new 52 week low
👍️0
Monksdream Monksdream 11 월 전
ACON new 52/week low
👍️0
Monksdream Monksdream 11 월 전
ACON new 52 week low
👍️0

최근 히스토리

Delayed Upgrade Clock